focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSPE.L Regulatory News (SPE)

  • There is currently no data for SPE

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

New capabilities with Accolade(R) 8.3

19 Jun 2013 07:00

RNS Number : 3163H
Sopheon PLC
19 June 2013
 



Embargoed Release: 07:00hrs, Wednesday 19th June, 2013

 

SOPHEON PLC

("Sopheon" or the "Company")

 

New capabilities for Enterprise Innovation Performance with Accolade® 8.3

 

Sopheon, the international provider of software, expertise, and best practices for Enterprise Innovation Performance, announced today the latest version of its Accolade innovation management solution. Accolade release 8.3 builds upon the enhancements provided in release 8.2 in January 2013 with a range of new and enhanced features, including:

 

• Increased capabilities and flexibility in the Innovation Planner solution for cross-functional planning and management of strategic business, market and product plans.

 

• Additional Portfolio Management and Analysis capabilities to quickly identify business needs and gaps across brands, business units and regions.

 

• Expanded Resource Planning functionality for managing, prioritizing and optimizing resources for innovation and new product development initiatives / projects.

 

• Additional support for companies to dynamically manage increased cadence and changes in operating plans with automatic financial forecast alignment and calculated metrics for quantifiable definition and tracking.

 

• Additional User Interface flexibility to personalize industry, company and end-user terminology.

 

This is the fourth Accolade product release by Sopheon over the past eighteen months, demonstrating our commitment to service customer needs and market trends with a regular timely cadence of product updates and enhancements. Sopheon's adoption of an agile product development process and using Accolade internally for managing all aspects of product planning, development and go-to-market have made this possible.

 

Don Sarno, Vice President of Product Development at Sopheon who has worked closely with customers and buyers over the past years, stated "Accolade Release 8.3 is a significant step forward to continue our industry leadership in Enterprise Innovation Planning and Portfolio Management."

 

Accolade® is a registered trademark of Sopheon.

 For further information contact:

Barry Mence, Chairman

Sopheon plc

+ 44 (0) 1483 685 735

Arif Karimjee, CFO

Sopheon plc

+ 44 (0) 1483 685 735

Charlotte Stranner / Victoria Bates

finnCap

+ 44 (0) 20 7600 1658

Heather Armstrong

Newgate Threadneedle

+ 44 (0) 20 7653 9842

Claire Verhagen

Citigate First Financial

+ 31 (0) 205 754 010

 

About Sopheon

Sopheon (LSE: SPE) partners with customers to provide complete Enterprise Innovation Performance solutions including software, expertise, and best-practices to achieve exceptional long-term revenue growth and profitability. Sopheon's Accolade® solution provides unique, fully-integrated coverage for the entire innovation management and new product development lifecycle. For the first time, businesses can access a single source of the truth across strategic innovation planning, roadmapping, idea and concept development, process and project management, and portfolio and in-market management. Sopheon's solutions have been implemented by over 200 customers with over 60,000 users in over 50 countries. Sopheon is listed on the AIM Market of the London Stock Exchange and on the Alternext Exchange in the Netherlands. For more information, please visit www.sopheon.com

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRAGGUBUQUPWGWR
Date   Source Headline
24th Jul 20199:05 amRNSSecond Price Monitoring Extn
24th Jul 20199:00 amRNSPrice Monitoring Extension
24th Jul 20197:00 amRNSTrading Update
13th Jun 20191:06 pmRNSResult of AGM
13th Jun 20197:00 amRNSAccolade 12.3
13th Jun 20197:00 amRNSAGM Statement
11th Jun 20191:32 pmRNSIssue of Equity
15th May 20197:00 amRNSSopheon Expands Customer Foothold in Asia
13th May 20199:14 amRNSIssue of Equity
28th Mar 20197:00 amRNSSopheon and National Foods Limited Partnership
21st Mar 20197:00 amRNSFinal Results
5th Feb 20197:00 amRNSIssue of Equity
29th Jan 20197:00 amRNSTrading Update
24th Jan 20194:41 pmRNSSecond Price Monitoring Extn
24th Jan 20194:35 pmRNSPrice Monitoring Extension
17th Jan 20197:00 amRNSAccolade Release 12.2
11th Jan 20197:00 amRNSTrading Update
8th Jan 20197:00 amRNSSopheon Partners with The Hershey Company
18th Dec 20182:53 pmRNSIssue of Equity
16th Nov 201812:54 pmRNSIssue of Equity
31st Oct 20185:18 pmRNSIssue of Equity
23rd Oct 20187:00 amRNSSopheon Awarded The Nature's Bounty Co. Business
8th Oct 20189:05 amRNSSecond Price Monitoring Extn
8th Oct 20189:00 amRNSPrice Monitoring Extension
8th Oct 20187:00 amRNSTrading Update
10th Sep 20187:00 amRNSDoosan Bobcat Awards Sopheon Innovation Contract
7th Sep 20185:48 pmRNSIssue of Equity
29th Aug 20183:54 pmRNSIssue of Equity & Holdings in Company
28th Aug 20187:00 amRNSAccolade Enterprise Innovation Management
23rd Aug 20187:00 amRNSHalf Yearly Report
19th Jul 201811:05 amRNSSecond Price Monitoring Extn
19th Jul 201811:00 amRNSPrice Monitoring Extension
19th Jul 20187:00 amRNSTrading Update
5th Jul 20189:40 amRNSGrant of Options / PDMR Dealing
3rd Jul 20189:24 amRNSIssue of Equity
13th Jun 20182:37 pmRNSIssue of Equity
7th Jun 201812:09 pmRNSResult of AGM
7th Jun 20187:00 amRNSAGM Statement
31st May 20182:56 pmRNSIssue of Equity
17th May 20188:01 amRNSResult of Secondary Placing
16th May 20183:05 pmRNSProposed Secondary Placing
15th May 20187:00 amRNSIssue of Equity
27th Apr 20183:59 pmRNSIssue of Equity
29th Mar 20187:00 amRNSAccolade Release 12.0
23rd Mar 20183:56 pmRNSIssue of Equity
23rd Mar 20187:00 amRNSIssue of Equity
22nd Mar 20187:00 amRNSFinal Results
20th Feb 20187:00 amRNSSopheon named in Annual Reader's Choice List
12th Feb 20189:24 amRNSGrant of Options / PDMR dealing
5th Feb 20183:35 pmRNSIssue of Equity

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.